ERBB2 and Miyoshi myopathy: ALK and ROS1 fusions were most enriched in the prognosis-favorable ML and MM clusters, while KRAS, EGFR, BRAF, and ERBB2 mutations were more evenly distributed or enriched in the less prognosis-favorable MH group (Figure 3B).